Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$22.80 USD
+2.30 (11.22%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.80 0.00 (0.00%) 4:30 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+2.30 (11.22%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.80 0.00 (0.00%) 4:30 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
Zacks News
Hims & Hers Health (HIMS) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Hims & Hers Health (HIMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stock to Buy for May 8th
by Zacks Equity Research
HIMS, CHRW and WRK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 8, 2024.
New Strong Buy Stocks for May 8th
by Zacks Equity Research
BRFS, GPS, GTN, HIMS and SIGA have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2024.
Hims & Hers Health, Inc. (HIMS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of 150% and 2.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Bears are Losing Control Over Hims & Hers Health (HIMS), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Hims & Hers Health (HIMS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Brokers Suggest Investing in Hims & Hers Health (HIMS): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Hims & Hers Health (HIMS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
P3 Health Partners Inc. (PIII) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
P3 Health Partners (PIII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Hims & Hers Health, Inc. (HIMS) Outpaced the Stock Market Today
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $12.50, signifying a +1.87% move from its prior day's close.
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) reachead $11.88 at the closing of the latest trading day, reflecting a -0.17% change compared to its last close.
Zacks Investment Ideas feature highlights: Hims & Hers Health, Coinbase Global
by Zacks Equity Research
Hims & Hers Health, Coinbase Global have been highlighted in this Investment Ideas article.
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $12.34, moving -0.56% from the previous trading session.
Investing in Growth: 2 Top-Ranked Stocks with Huge Potential
by Ethan Feller
Strong sales growth is a beacon for investors seeking promising companies
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $14.60, denoting a +0.34% change from the preceding trading day.
What Makes Hims & Hers Health, Inc. (HIMS) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
by Zacks Equity Research
Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.
Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 70.2% upside potential for Hims & Hers Health, Inc. (HIMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -33.33% and 3.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 50% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 20% and 5.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 19.61% and 9.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?